John is a 56-year-old male admitted to the ICU with severe community-acquired pneumonia. His medical history includes type 2 diabetes and hypertension. He was started empirically on broad-spectrum antibiotics including piperacillin-tazobactam and vancomycin. Initial cultures are pending, and rapid multiplex PCR testing has been ordered. The ICU team is considering antibiotic de-escalation but is concerned about patient safety given his critical illness.

Based on current evidence from the multicenter observational study, what is the most appropriate pharmacist recommendation regarding antibiotic de-escalation for John?

Maria is a 62-year-old female in the ICU with septic shock secondary to a urinary tract infection. She is on vasopressors and broad-spectrum antibiotics. The ICU team is hesitant to de-escalate antibiotics due to concerns about patient safety and delayed culture results. As the clinical pharmacist, you are asked to provide guidance on improving antibiotic stewardship practices in this setting.

What pharmacist-led intervention is most supported by the study to overcome barriers to antibiotic de-escalation in ICU patients like Maria?

David is a 70-year-old male admitted to the ICU with ventilator-associated pneumonia. He has multiple comorbidities including chronic kidney disease and heart failure. The ICU recently implemented an antimicrobial stewardship program focusing on antibiotic de-escalation protocols. David’s cultures show a susceptible pathogen, and the team is considering narrowing therapy. The pharmacist is asked to support this process.

Which action best aligns with evidence-based stewardship practices to optimize antibiotic use for David?